Literature DB >> 30565303

Clear cell renal cell carcinoma with wild-type von Hippel-Lindau gene: a non-existent or new tumour entity?

Aashil A Batavia1, Peter Schraml1, Holger Moch1.   

Abstract

The current World Health Organisation (WHO) classification of renal tumours is based on characteristic histological features or specific molecular alterations. von Hippel-Lindau (VHL) alteration is the hallmark of clear cell renal cell carcinoma (RCC). After identification of the MiT translocation family of tumours, clear cell papillary renal cancer and others, the group of ccRCC with wild-type VHL is small. TCEB1 mutation combined with chromosome 8q loss is an emerging tumour entity with wild-type VHL. Inactivation of TCEB1 increases HIF stabilisation via the same mechanism as VHL inactivation. Importantly, recent molecular analyses suggest the existence of another 'VHL wild-type' evolutionary subtype of clear cell RCC in addition to TCEB1 mutated RCC and clear cell papillary renal cancer. These tumours are characterised by an aggressive behaviour, high tumour cell proliferation rate, elevated chromosomal instability and frequent presence of sarcomatoid differentiation. Future clinicopathological studies will have to provide data to determine whether TCEB1 tumours and clear cell RCC with wild-type VHL are separate tumour entities or represent variants of a clear cell RCC tumour family.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  TCEB1-deficient ccRCC; VHL wild-type; clear cell renal cell carcinoma

Mesh:

Substances:

Year:  2019        PMID: 30565303     DOI: 10.1111/his.13749

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  8 in total

1.  HLA-I-restricted CD8+ T cell immunity may accelerate tumorigenesis in conjunction with VHL inactivation.

Authors:  BeumJin Park; Seok-Jae Heo; Yong Joon Lee; Mi-Kyoung Seo; Jiyun Hong; Eui-Cheol Shin; Inkyung Jung; Sangwoo Kim
Journal:  iScience       Date:  2022-05-25

Review 2.  [Characterization of different renal cell carcinoma entities].

Authors:  N J Rupp; H Moch
Journal:  Urologe A       Date:  2020-02       Impact factor: 0.639

3.  Spatial Distribution of Private Gene Mutations in Clear Cell Renal Cell Carcinoma.

Authors:  Ariane L Moore; Aashil A Batavia; Jack Kuipers; Jochen Singer; Elodie Burcklen; Peter Schraml; Christian Beisel; Holger Moch; Niko Beerenwinkel
Journal:  Cancers (Basel)       Date:  2021-04-30       Impact factor: 6.575

Review 4.  Towards a new WHO classification of renal cell tumor: what the clinician needs to know-a narrative review.

Authors:  Alessia Cimadamore; Liang Cheng; Marina Scarpelli; Francesco Massari; Veronica Mollica; Matteo Santoni; Antonio Lopez-Beltran; Rodolfo Montironi; Holger Moch
Journal:  Transl Androl Urol       Date:  2021-03

5.  Identification of aberrantly methylated-differentially expressed genes and potential agents for Ewing sarcoma.

Authors:  Guowang Li; Xuan Zhou; Lijun Tian; Gedong Meng; Bo Li; Hao Yu; Yongjin Li; Zhenxin Huo; Lilong Du; Xinlong Ma; Baoshan Xu
Journal:  Ann Transl Med       Date:  2021-10

6.  Whole-Exome Sequencing Identifies the VHL Mutation (c.262T > C, p.Try88Arg) in Non-Obstructive Azoospermia-Associated Cystic Renal Cell Carcinoma.

Authors:  Yonghong Man; Xuejun Shang; Chunyu Liu; Wei Zhang; Qian Huang; Suheng Ma; Rita Shiang; Feng Zhang; Ling Zhang; Zhibing Zhang
Journal:  Curr Oncol       Date:  2022-03-28       Impact factor: 3.109

7.  Functional deficiency of succinate dehydrogenase promotes tumorigenesis and development of clear cell renal cell carcinoma through weakening of ferroptosis.

Authors:  Jing Yang; Yi Zhou; Yanchun Li; Wanye Hu; Chen Yuan; Shida Chen; Gaoqi Ye; Yuzhou Chen; Yunyi Wu; Jing Liu; Ying Wang; Jing Du; Xiangmin Tong
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

8.  HIF-1α and HIF-2α differently regulate tumour development and inflammation of clear cell renal cell carcinoma in mice.

Authors:  Rouven Hoefflin; Sabine Harlander; Silvia Schäfer; Patrick Metzger; Fengshen Kuo; Désirée Schönenberger; Mojca Adlesic; Asin Peighambari; Philipp Seidel; Chia-Yi Chen; Miguel Consenza-Contreras; Andreas Jud; Bernd Lahrmann; Niels Grabe; Danijela Heide; Franziska M Uhl; Timothy A Chan; Justus Duyster; Robert Zeiser; Christoph Schell; Mathias Heikenwalder; Oliver Schilling; A Ari Hakimi; Melanie Boerries; Ian J Frew
Journal:  Nat Commun       Date:  2020-08-17       Impact factor: 14.919

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.